These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7823612)

  • 1. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
    Lipkin M
    J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate endpoint biomarker assays in phase II chemoprevention clinical trials.
    Lipkin M; Bhandari M; Hakissian M; Croll W; Wong G
    J Cell Biochem Suppl; 1994; 19():47-54. PubMed ID: 7823605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of colon carcinogenesis by the natural product of a simple phenolic compound protocatechuic acid: suppressing effects on tumor development and biomarkers expression of colon tumorigenesis.
    Tanaka T; Kojima T; Suzui M; Mori H
    Cancer Res; 1993 Sep; 53(17):3908-13. PubMed ID: 8358716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of rectal epithelial kinetic patterns as an intermediate biomarker of colon cancer.
    Anti M; Marra G; Percesepe A; Armelao F; Gasbarrini G
    J Cell Biochem Suppl; 1994; 19():68-75. PubMed ID: 7823608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early development of cancer chemoprevention clinical trials: studies of dietary calcium as a chemopreventive agent for human subjects.
    Lipkin M
    Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S65-70. PubMed ID: 12570337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat.
    Wargovich MJ; Chen CD; Jimenez A; Steele VE; Velasco M; Stephens LC; Price R; Gray K; Kelloff GJ
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):355-60. PubMed ID: 9162301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
    Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
    Krishnan K; Ruffin MT; Brenner DE
    J Cell Biochem Suppl; 1997; 28-29():148-58. PubMed ID: 9589361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
    Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
    J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci.
    Ziliotto L; Barbisan LF; Rodrigues MA
    Hum Exp Toxicol; 2008 Jun; 27(6):505-11. PubMed ID: 18784204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New rodent models for studies of chemopreventive agents.
    Lipkin M
    J Cell Biochem Suppl; 1997; 28-29():144-7. PubMed ID: 9589360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
    Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
    J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer.
    Tao L; Wang W; Kramer PM; Lubet RA; Steele VE; Pereira MA
    Mol Carcinog; 2004 Feb; 39(2):79-84. PubMed ID: 14750212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.